Learning outcomes:
The overall learning objectives of the Best of ASCO 2026 is to provide participants with the latest expert consensus thinking and the most important research findings for the treatment and management of common and rare cancers.
Specifically, participants will be able to:
- Enable HMC cancer professionals to identify the latest research findings and evaluate the implications for treatment options for common tumors such as breast, colon, lung, and prostate cancers.
- Identify the latest research findings and evaluate the implications for the care and management of rare cancer such as neurological, head and neck, urological, gynecology and sarcoma
- Identify and evaluate the implications of advances in emerging therapies such as immunotherapy, molecular precision medicine and tumor biology for HMC’s cancer practice and research
- Identify and evaluate the latest approaches to symptom management and survivorship in order shape HMC’s cancer services
